Amneal Pharmaceuticals, LLC
Amneal Pharmaceuticals, LLC
Explore linked clinical trials.5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Mycophenolate Pregnancy Registry | autoimmune disease, immune system disorder | Recruiting | Not stated | 2026-10-06 | NCT01733082 | |
| BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 4 | 2026-06-23 | NCT07138560 | |
| A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 4 | 2025-08-24 | NCT06765668 | |
| Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People. | Blood-Borne Infections, DNA Virus Infections, Digestive System Diseases, Genital Diseases, HIV infectious disease, Hepadnaviridae infectious disease, Infections, RNA Virus Infections, Urogenital Diseases, hepatitis, hepatitis B virus infection, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, liver disorder, sexually transmitted disease, uterine carcinosarcoma, viral hepatitis, viral infectious disease, viral sexually transmitted disease | Recruiting | Not stated | 2025-04-01 | NCT00404989 | |
| Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes. | eye disorder, glaucoma, ocular hypertension, open-angle glaucoma | Recruiting | Phase 3 | 2022-08-10 | NCT05401357 |